Zivo Bioscience, Inc.
ZIVO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001101026
No open-market purchases or sales by Zivo Bioscience, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17.6K in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Zivo Bioscience, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 12 | 14 | +2 |
| Shares | 181.5K | 578.1K | +396.7K (+218.6%) |
| Value | $828.6K | $1.66M | +$828.4K (+100.0%) |
New holders (8)
Institutions that held Zivo Bioscience, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 341,680 | $980.0K | 0.00% |
| Vanguard Group Inc | 77,321 | $221.0K | 0.00% |
| Schechter Investment Advisors, LLC | 56,770 | $163.0K | 0.01% |
| CoreCap Advisors, LLC | 26,166 | $75.0K | 0.01% |
| Citadel Advisors LLC | 25,483 | $73.0K | 0.00% |
| XTX Topco Ltd | 22,976 | $66.0K | 0.04% |
| Royal Bank of Canada | 1,875 | $5.00K | 0.00% |
| Bourgeon Capital Management LLC | 31 | $0 | 0.00% |
Sold out (6)
Institutions that held Zivo Bioscience, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Credit Suisse AG | 45,132 | $206.0K |
| Jane Street Group, LLC | 41,934 | $191.0K |
| Two Sigma Investments, LP | 31,367 | $143.0K |
| Two Sigma Securities, LLC | 30,260 | $138.0K |
| Bartlett & Co. LLC | 1,000 | $5.00K |
| Bartlett & Co. Wealth Management LLC | 1,000 | $4.56K |